|Slideshows|October 21, 2016

Psychiatric Fallout From Toxic Exposure

Author(s)James S. Brown, Jr, MD, MPH, MS

A growing body of scientific literature associates psychiatric symptoms with man-made toxic substances and environmental exposure. Practical implications for psychiatrists are discussed in this Special Report collection.

To view the information in PDF format, click here.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Kratom Component in Clinical Trial for Opioid Use Disorder

ByKenneth J. Bender, PharmD, MA

August 21st 2026

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG

ByKazu Okuda, MD

August 21st 2026

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

ByLeah Kuntz

August 20th 2026

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care

ByChristian Heidbreder, PhD

August 20th 2026

Let’s Talk About Drug Testing

ByEvan S. Schwarz, MD, FACEP, FACMT, FASAM

August 19th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Psychiatric Fallout From Toxic Exposure

Related Content

Kratom Component in Clinical Trial for Opioid Use Disorder

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care

Let’s Talk About Drug Testing

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Kratom Component in Clinical Trial for Opioid Use Disorder

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

Why Cultural Context Matters in Psychiatric Assessment

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG